共查询到18条相似文献,搜索用时 81 毫秒
1.
目的:研究汉族妇女中MDM2基因SNP309多态性与宫颈癌易感性及临床病理学参数之间的关系。方法:用DNA抽提试剂盒从研究对象的外周血标本中抽提基因组DNA, 其中宫颈癌患者105例, 正常对照组140例; 用聚合酶链式反应-限制性片段长度多态 (PCR-RFLP) 和直接测序方法测定MDM2-SNP309单核苷酸多态基因型。结果:宫颈癌患者的MDM-SNP309 G等位基因频率显著高于对照组 (60.0% vs 48.6%, P=0.012; OR=1.59, 95% CI=1.11~2.28); 宫颈癌与对照组之间的GG、 TG和TT等位基因型的分布差异有统计学意义, 其中GG等位基因型在宫颈细胞癌中的频率显著高于对照组 (36.2% vs 18.6%, P=0.016; OR=2.58,95% CI=1.19~5.61)。在宫颈癌组中, 淋巴转移阳性组MDM2-SNP309 GG等位基因型显著高于淋巴转移阴性组 (31.8% vs 11.5%, P<0.05), SNP309单核苷酸多态性分布与肿瘤组织学类型、病理分级及肿瘤大小无关。结论:MDM2基因SNP309 GG基因型是宫颈癌发生的遗传易感因素, 与宫颈癌的淋巴转移发生有相关性。 相似文献
2.
目的:采用病例- 对照研究检测MDM2 启动子区309 位点T>G 单核苷酸多态(SNP 309)在中国女性人群中的频率分布,分析其与中国女性乳腺癌发病风险的关系。方法:提取病例组698 例原发性乳腺癌患者及对照组525 例健康人的外周血单核细胞DNA,采用聚合酶链反应- 限制性片段长度多态性(PCR-RFLP )分析法,检测MDM2 启动子区309 位点基因多态性,确定此位点三种基因型,即T/T、T/G、G/G 基因型。统计分析病例组和对照组人群MDM2 SNP 309 各基因型频率分布,及各基因型与乳腺癌发病风险的相关性。结果:在研究的病例组与对照组整体人群中,经年龄、月经状态、家族史及生育史等因素校正后,与MDM2 SNP 309 T/T基因型比较,T/G 型及G/G 型与乳腺癌的发病风险无显著相关性(T/G,adjusted OR= 1.2,95%CI:0.8~1.6,P=0.30;G/G,adjusted OR= 1.0,95%CI:0.7~1.5,P=0.88)。 进一步分层分析后显示:在绝经后人群中,与T/T基因型比较,T/G 基因型及G/G 基因型显著增加乳腺癌的发病风险(T/G,adjusted OR= 1.8,95%CI:1.2~3.0,P=0.011;G/G,adjusted OR= 1.9,95%CI:1.2~3.3,P=0.014)。 提示绝经后人群携带T/G 型、G/G 型者比携带T/T基因型者患乳腺癌的风险分别升高约1.8、1.9 倍。在绝经前人群中,各基因型与乳腺癌的发病风险无显著相关性(P>0.05)。 结论:MDM2 启动子309 位点突变型G 等位基因携带者显著增加绝经后女性乳腺癌的发病风险。 相似文献
3.
[目的]综合评价MDM2(routine double minute2)基因启动子309位点多态性与乳腺癌易感性的关系。[方法]检索中国医学文献数据库和PubMed中MDM2基因SNP309与乳腺癌易感性关系的病例对照研究,并用Meta分析的方法合并SNP309与乳腺癌易感性OR值。然后进行其中有家族史的乳腺癌亚组分析,敏感性分析和文献的发表偏倚检验。[结果]Meta分析共纳入10篇文献,乳腺癌家族史组有3篇;累计病例7535例,对照8272例,G等位基因相对于T等位基因0R值为1.01(95%CI:0.96~1.06)。乳腺癌家族史组G等位基因相对于T等位基因OR值为1.06(95%CI:0.94~1.19)。[结论]MDM2基因309T〉G多态与乳腺癌易感性无统计学意义。 相似文献
4.
背景与目的:MDM2基因是p53基因的负性调控因子,其SNP309遗传多态性可能与乳腺癌发病风险有关,本研究探讨SNP309多态性在福建早发性乳腺癌人群中的分布及其与乳腺癌发病风险的相关性.方法:对123例早发性乳腺癌患者(发病年龄≤35岁)和101例正常对照者进行MDM2基因SNP309(T>G,rs2279744)的PCR扩增,并采用时间飞行质谱分析(MALDI-TOF-MS)法鉴定多态性的基因型,比较基因型分布和发病风险的关系;危险度OR及95%CI应用非条件Logistic回归分析计算.结果:MDM2基因SNP309多态性基因型在正常对照组和病例组中的分布频率分别为TT:28(27.7%)/26(21.1%),TG:50(49.5%)/61(49.6%),GG:23(22.8%)/36(29.3%);两组间分布频率差异无统计学意义(P>0.05).Logistic回归分析表明,在早发性乳腺癌人群中,以rs2279744的TT基因型为参照,含G基因型(TG,GG)未显著性地提高乳腺癌的发病危险,OR=1.358(95%CI:0.706~2.614,P>0.05).结论:MDM2基因SNP309(T>G,rs2279744)多态性可能与福建地区汉族人群早发性乳腺癌的遗传易感性无关,其作为低外显率的乳腺癌易感基因位点尚不明确,作为未来临床基因筛查的候选指标还需谨慎. 相似文献
5.
研究表明鼠双微体2(murine double minute 2,MDM2)基因的扩增和(或)过度表达可见于多种肿瘤,如淋巴瘤,乳腺癌和睾丸精子细胞肿瘤,MDM2在肺癌中的表达是一个常见现象。因此,MDM2在非小细胞肺癌(NSCLC)易感性及辐射敏感性中的作用是值得肿瘤学家们探讨的问题,笔者采用PCR-RFLP方法检测80例NSCLC及82例正常人MDM2基因单核苷酸多态性(SNP),旨在探讨MDM2基因多态性与NSCLC易感性及辐射敏感性是否存在相关性。 相似文献
6.
目的:综合评价MDM2 (murine double minute 2)基因启动子309位点多态性与肺癌易感性的关系.方法:检索中国医学文献数据库和PubMed,以得到MDM2基因SNP309与肺癌易感性关系的病例对照研究,并用Meta分析的方法合并SNP309与肺癌易感性关系的OR值.然后进行亚组分析、敏感性分析和文献的发表偏倚检验.结果:本次Meta分析共纳入6篇文献,累计病例4276例,对照5318例,G等住基因相对于T等位基因OR值为1.11(95%CI为0.97~1.26,P=0.14),差异无统计学意义,但在未吸烟亚组中OR值为1.32(95%CI为1.15~1.52,P=0.000),差异有统计学意义.结论:MDM2基因309T>G多态与肺癌易感性的关系差异无统计学意义,但在未吸烟亚组中SNP309G等位基因是一个肺癌危险因子. 相似文献
7.
目的:探讨小鼠双微体基因(murine double minute 2,MDM2)单核苷酸多态性(SNP)与肝细胞肝癌易感性及生物学行为的关系。方法:对166例肝癌病例和157例健康对照病例的外周血标本,利用SYBRGREEN PCR溶解曲线法分析MDM2基因型。结果:实验组等位基因的发生率(T,0.49;G,0.51)与对照组基因的发生率(T,0.59;G,0.41)(P=0.015)有统计学差异。肝癌患者中GG基因型的发生率(22.29%)高于健康人群(13.38%)(P=0.010)。结论:与TT基因型相比,携带G等位基因或GG型与肝癌发生的相关性较大。 相似文献
8.
目的:探讨MDM2基因rs2279744多态性与肝细胞癌(HCC)的发病及预后的关系。方法:采用以医院为基础的病例-对照研究方式通过TaqMan-PCR检测分析192例HCC患者和192名健康志原者的MDM2基因rs2279744的基因型,通过Logistic回归、Kaplan-Meier法和Cox比例风险回归模型等分析该多态性与HCC发病及预后的关系。结果:带有MDM2rs2279744G等位基因的基因型(MDM2-TG和-GG)在HCC组的频率要高于对照组(P=1.77×10-9),与不带有G等位基因者(MDM2-TT)相比,其所致HCC发病风险分别为2.86(1.68~4.85)和4.84(2.90~8.09);该多态性增加肿瘤血道转移风险(OR=1.75);生存分析显示,MDM2-TG和-GG影响HCC术后无病生存及总体生存(P<0.01)。结论:MDM2基因rs2279744多态性影响HCC发病及预后。 相似文献
9.
背景与目的:环境因素在前列腺癌发病机制中的作用,尤其是高脂肪摄入饮食、缺乏体力活动等引起的肥胖逐渐受到重视。脂联素可能是前列腺癌与肥胖之间潜在的分子递质,本研究旨在探讨编码脂联素的ADIPOQ基因多态性与中国人群前列腺癌发病风险的关联性。方法:提取917例前列腺癌患者和1 036例正常对照男性的外周血DNA,通过TaqMan探针技术检测ADIPOQ基因rs266729和rs182052的多态性。采用Logistic回归模型分析各基因型与前列腺癌发病风险的关系,在此基础上分析其与体质量指数的关系。结果:对照组中rs266729和rs182052两位点的基因型频率均符合Hardy-Weinberg平衡(P=0.29和0.83)。rs266729和rs182052两位点各基因型在两组间的分布差异无统计学意义(P=0.88和0.63)。与野生型相比,两位点的杂合型及突变型携带者患病风险差异无统计学意义(OR=0.97,95%CI:0.81~1.16;OR=0.89,95%CI:0.73~1.09)。分层分析显示,在年龄≤69岁的人群中,rs182052 AA基因型携带者的前列腺癌发病风险仅为AG或GG基因型携带者的73%(95%CI:0.54~0.99),差异有统计学意义(P=0.04)。rs182052遗传变异与体质量指数相关(P=0.03)。结论:ADIPOQ基因rs266729和rs182052可能与中国人群前列腺癌总体发病风险无关,rs182052 AA基因型携带者≤69岁时发病风险较低,并且该位点的遗传变异与前列腺癌患者的体质量指数相关。 相似文献
10.
目的 探讨Asp299Gly(rs4986790)、Thr399Ile(rs4986791)、rs11536889单核苷酸多态性(SNP)与前列腺癌(PCa)易感性和严重程度的关系.方法 采用病例对照研究方法,选取组织学证据确诊的PCa患者96例为PCa组,良性前列腺增生(BPH)患者87例为BPH组,健康者92例为健康对照组.记录研究对象的临床资料并计算Gleason评分,PCR-RFLP法分析各组的基因型.结果 PCa组、BPH组及健康对照组的年龄、前列腺癌家族史所占比例、前列腺特异抗原(PSA)水平比较,差异均有统计学意义(P=0.000);PCa组、BPH组及健康对照组的Asp299Gly和Thr399Ile基因型频率分布比较,差异无统计学意义(P﹥0.05),但3组间rs11536889基因型频率分布比较,差异有统计学意义[PCa组/(BPH组+健康对照组),CC/GC vs GG,OR=2.152,95%CI:1.280~3.618,P﹤0.05];Gleason评分≥7分组GC+CC分布比例高于Gleason评分﹤7分组(OR=2.378,95%CI:1.042~4.427,P﹤0.05).结论 TLR4基因rs11536889 SNP可能与PCa发病和病情严重程度相关. 相似文献
11.
12.
13.
Johansson M Holmström B Hinchliffe SR Bergh A Stenman UH Hallmans G Wiklund F Stattin P 《International journal of cancer. Journal international du cancer》2012,130(1):129-137
The aim of this study was to investigate if a genetic risk score including 33 common genetic variants improves prediction of prostate cancer when added to measures of prostate-specific antigen (PSA). We conducted a case-control study nested within the Northern Sweden Health and Disease Cohort (NSHDC), a prospective cohort in northern Sweden. A total of 520 cases and 988 controls matched for age, and date of blood draw were identified by linkage between the regional cancer register and the NSHDC. Receiver operating characteristic curves with area under curve (AUC) estimates were used as measures of prostate cancer prediction. The AUC for the genetic risk score was 64.3% [95% confidence interval (CI) = 61.4-67.2], and the AUC for total PSA and the ratio of free to total PSA was 86.2% (95% CI = 84.4-88.1). A model including the genetic risk score, total PSA and the ratio of free to total PSA increased the AUC to 87.2% (95% CI = 85.4-89.0, p difference = 0.002). The addition of a genetic risk score to PSA resulted in a marginal improvement in prostate cancer prediction that would not seem useful for clinical risk assessment. 相似文献
14.
15.
Johansson M McKay JD Stattin P Canzian F Boillot C Wiklund F Adami HO Bälter K Grönberg H Kaaks R 《International journal of cancer. Journal international du cancer》2007,120(3):539-542
Insulin-like growth factor-I (IGF1) stimulates cell proliferation, decreases apoptosis, and has been implicated in cancer development. Epidemiological studies have shown elevated levels of circulating IGF1 to be associated with increased risk of prostate cancer. To what extent genetic variation in the IGF1 gene is related to prostate cancer risk is largely unknown. We performed a comprehensive haplotype tagging (HT) assessment of single nucleotide polymorphisms (SNPs) representing the common haplotype variation in the IGF1 gene. We genotyped 10 SNPs (9 haplotype tagging SNPs (htSNPs)) within Cancer Prostate in Sweden (CAPS), a case-control study of 2,863 cases and 1,737 controls, in order to investigate if genetic variation in the IGF1 gene is associated with prostate cancer risk. Three haplotype blocks were identified across the IGF1 gene and 9 SNPs were selected as haplotype tagging SNPs. Common haplotypes in the block covering the 3' region of the IGF1 gene showed significant global association with prostate cancer risk (p = 0.004), with one particular haplotype giving an odds ratio of 1.46 (95% CI = 1.15-1.84, p = 0.002). This haplotype had a prevalence of 5% in the study population. Our results indicate that common variation in the IGF1 gene, particularly in the 3' region, may affect prostate cancer risk. Further studies on genetic variations in the IGF1 gene in relation to prostate cancer risk as well as to circulating levels of IGF1 are needed to confirm this novel finding. 相似文献
16.
17.
Chia‐Cheng Yu Chao‐Yuan Huang Victor C. Lin I‐Che Chung Lih‐Chyang Chen Isabelle Laverdière Louis Lacombe Yves Fradet Ta‐Yuan Chang Hong‐Zin Lee Shin‐Hun Juang Bo‐Ying Bao 《International journal of cancer. Journal international du cancer》2014,135(11):2661-2667
Recent evidence indicates that microRNAs might participate in prostate cancer initiation, progression and treatment response. Germline variations in microRNAs might alter target gene expression and modify the efficacy of prostate cancer therapy. To determine whether genetic variants in microRNAs and microRNA target sites are associated with the risk of biochemical recurrence (BCR) after radical prostatectomy (RP). We retrospectively studied two independent cohorts composed of 320 Asian and 526 Caucasian men with pathologically organ‐confined prostate cancer who had a median follow‐up of 54.7 and 88.8 months after RP, respectively. Patients were systematically genotyped for 64 single‐nucleotide polymorphisms (SNPs) in microRNAs and microRNA target sites, and their prognostic significance on BCR was assessed by Kaplan–Meier analysis and Cox regression model. After adjusting for known clinicopathologic risk factors, two SNPs (MIR605 rs2043556 and CDON rs3737336) remained associated with BCR. The numbers of risk alleles showed a cumulative effect on BCR [perallele hazard ratio (HR) 1.60, 95% confidence interval (CI) 1.16–2.21, p for trend = 0.005] in Asian cohort, and the risk was replicated in Caucasian cohort (HR 1.55, 95% CI 1.15–2.08, p for trend = 0.004) and in combined analysis (HR 1.57, 95% CI 1.26–1.96, p for trend <0.001). Results warrant replication in larger cohorts. This is the first study demonstrating that SNPs in microRNAs and microRNA target sites can be predictive biomarkers for BCR after RP. 相似文献
18.
单核苷酸基因多态(SNP)是指在基因组DNA序列中频率大于1%的单个核苷酸的变异.这种基因组DNA的微小变化(基因型)有时导致其编码的蛋白质结构和功能发生改变.在乳腺癌患者中,不同SNP基因型患者经过治疗后的预后不同.通过研究发现与乳腺癌患者预后密切相关的SNP,有助于实现治疗和随访的个体化,并为临床治疗决策提供重要的依据. 相似文献